Eli Lilly acquisitions, on the record

Word for word“In December 2023, we acquired all shares of POINT for a purchase price of $ 12.50 per share in cash (or an aggregate of $ 1.04 billion, net of cash acquired).” 10-K for 2023

Word for word“Acquired in the acquisition of Versanis Bio, Inc. (Versanis) in 2023.” 10-K for 2023

Word for word“Acquired in the acquisition of DICE Therapeutics, Inc. (DICE) in 2023.” 10-K for 2023

Word for word“For investments that were accounted for as asset acquisitions, we paid $3.94 billion in 2023 for acquired IPR&D primarily related to acquisitions of DICE, Versanis, Emergence Therapeutics AG (Emergence), and Mablink Biosciences SAS (Mablink).” 10-K for 2023

Word for word“For investments that were accounted for as asset acquisitions, we paid $3.94 billion in 2023 for acquired IPR&D primarily related to acquisitions of DICE, Versanis, Emergence Therapeutics AG (Emergence), and Mablink Biosciences SAS (Mablink).” 10-K for 2023

Word for word“Outside the U.S. the increase in volume in 2023 was primarily driven by $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, as well as increased volume for Verzenio and Jardiance.” 10-K for 2023

Word for word“In the U.S. the increase in volume in 2023 was primarily driven by Mounjaro, Verzenio, Jardiance, Trulicity, Taltz ® , and Zepbound and $579.0 million from the sale of the rights for Baqsimi, partially offset by the absence of revenue from COVID-19 antibodies and decreased volume from Alimta following the entry of multiple generics in the first half of 2022.” 10-K for 2023

Word for word“In May 2024, we acquired all outstanding membership interests of NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $ 924.7 million, net of cash acquired.” 10-K for 2024

Word for word“In December 2022, we acquired all shares of Akouos, Inc. (Akouos) for a purchase price that included $ 12.50 per share in cash (or an aggregate of $ 327.2 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share.” 10-K for 2024

Word for word“MORF-057 Crohn's disease Phase 2 Acquired in the acquisition of Morphic Holding, Inc. (Morphic) in 2024.” 10-K for 2024

Word for word“In July 2025, we acquired all shares of Verve Therapeutics, Inc. (Verve) for a purchase price of $ 10.50 per share in cash (or an aggregate of $ 549 million, net of cash acquired), plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $ 3.00 per share (or an aggregate of up to approximately $ 300 million) payable, subject to certain terms and conditions, upon the achievement of a certain specified milestone.” 10-K for 2025

Word for word“In December 2023, we acquired all shares of POINT Biopharma Global Inc. (POINT) for a purchase price of $ 12.50 per share in cash (or an aggregate of $ 1.0 billion, net of cash acquired).” 10-K for 2025

Word for word“In 2023, we sold the rights for the olanzapine portfolio, including Zyprexa, a neuroscience product, to Cheplapharm Arzneimittel GmbH, a European company.” 10-K for 2025